What is William Blair’s Estimate for NKTR Q2 Earnings?
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities researchers at William Blair reduced their Q2 2025 EPS estimates for Nektar Therapeutics in a research note issued on Monday, May 12th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.20) per share for the quarter, down from their previous forecast of […]
Nektar Therapeutics (NASDAQ:NKTR – Free Report) – Equities researchers at William Blair reduced their Q2 2025 EPS estimates for Nektar Therapeutics in a research note issued on Monday, May 12th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn ($0.20) per share for the quarter, down from their previous forecast of […]
